Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
28 studies found for:    " July 17, 2011":" August 16, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" July 17, 2011":" August 16, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (28 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
2 Completed A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
Condition: Human Immunodeficiency Virus
Intervention: Drug: P2G12
3 Completed
Has Results
Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi
Condition: HIV
Interventions: Other: Home assessment and initiation of ART;   Other: Clinic-based ART assessment and initiation
4 Recruiting Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Conditions: Leukemia;   Lymphoma;   HIV
Interventions: Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan;   Drug: Busulfan and Fludarabine;   Drug: Cyclophosphamide and Total Body Irradiation
5 Completed Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
Condition: HIV
Intervention: Dietary Supplement: Moringa oleifera
6 Completed Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA HIVIS and MVA-CMDR;   Biological: Saline solution
7 Unknown  HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users
Conditions: HIV;   Drug Use Disorders
Interventions: Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
8 Unknown  Depression and ART Adherence in HIV+ Latinos
Conditions: Depressive Symptoms;   HIV Infections
Intervention: Behavioral: Cognitive-Behavioral Therapy AD
9 Unknown  Stanford Universities: The Stanford HIV Aging Cohort
Condition: Acquired Immunodeficiency Syndrome
Intervention:
10 Completed HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
Conditions: Acquired Immunodeficiency Syndrome;   Stress Disorders, Post-Traumatic
Intervention: Behavioral: Questionnaires
11 Recruiting Eplerenone in HIV Associated Abdominal Fat Accumulation
Condition: HIV
Interventions: Drug: Eplerenone and lifestyle;   Other: placebo and lifestyle
12 Active, not recruiting Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care
Condition: HIV-infection/Aids
Intervention: Behavioral: Health Navigator
13 Recruiting Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Conditions: Liver Diseases, Alcoholic;   Alcoholism;   HIV;   Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC);   Other: Treatment as Usual
14 Completed
Has Results
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
Condition: HIV
Interventions: Drug: Atazanavir (current formulation);   Drug: Atazanavir, powder for oral use 1  (POU1);   Drug: Atazanavir (POU2)
15 Completed
Has Results
Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy
Conditions: HIV;   AIDS;   Peripheral Neuropathy;   Pain;   Sleep
Interventions: Device: Splinting application to the lower extremities;   Device: Splint liner application
16 Active, not recruiting Adolescent Master Protocol
Condition: HIV/AIDS
Intervention:
17 Unknown  Centralized Off-Site Adherence Enhancement Program
Condition: HIV/AIDS
Intervention: Behavioral: cognitive-behavioral therapy
18 Recruiting the " Extreme " Cohort (CODEX)
Condition: HIV Infection
Intervention: Biological: blood sampling
19 Terminated Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
Conditions: HIV Infection;   Tuberculosis
Interventions: Drug: Experimental: Empiric TB treatment;   Drug: ART only arm
20 Active, not recruiting Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Indicates status has not been verified in more than two years